Aclaris Therapeutics(US:ACRS) Globenewswireยท2025-02-27 11:59Core Insights - Aclaris Therapeutics is positioned for multiple clinical catalysts in 2025, particularly with Phase 2 data for bosakitug in severe asthma and chronic rhinosinusitis with nasal polyps expected in the first half of 2025 [1][3] - The company has a strong cash runway expected to last into 2028, bolstered by a recent $80 million private placement [5][7] Pipeline Developments - Aclaris has announced an exclusive global license agreement with Biosion, acquiring rights to bosakitug (ATI-045) and ATI-052, which are potential best-in-class biologic assets [4] - Phase 2 studies for bosakitug in Chinese patients with severe asthma and chronic rhinosinusitis are ongoing, with data expected in the first half of 2025 [4][3] - A Phase 2b trial for bosakitug in atopic dermatitis is set to begin enrollment in the first half of 2025 [1][4] - Top-line results from a Phase 2a trial of ATI-2138 in atopic dermatitis are also anticipated in the first half of 2025 [3][4] Financial Performance - For Q4 2024, Aclaris reported a net loss of $96.6 million, compared to a net loss of $1.5 million in Q4 2023 [8] - Total revenue for Q4 2024 was $9.2 million, down from $17.6 million in Q4 2023, primarily due to a one-time payment received in the previous year [9] - Research and development expenses decreased to $9.0 million in Q4 2024 from $26.6 million in the prior year [10] - General and administrative expenses also saw a reduction, totaling $5.0 million in Q4 2024 compared to $8.2 million in Q4 2023 [11] Leadership Changes - Dr. Neal Walker has been appointed as the Chief Executive Officer, bringing extensive experience as a co-founder of Aclaris [14] - Hugh Davis has joined as President and Chief Operating Officer, contributing over 35 years of experience in biologics development [14]